Clinical trial
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With…
NCT00047255 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00047255 |
|---|---|
| Title | Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer |
| Official title | A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, carboplatin, docetaxel, trastuxumab, Docetaxel |
| Enrollment | 263 |
| Start date | May 1, 2002 |
| Primary completion | Jan 1, 2006 |
| Completion | Apr 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: